A novel experimental strategy to assess the metabolic effects of selective activation of a Gq- coupled receptor in hepatocytes in vivo

Endocrinology

Volumn 154, Issue 10, 2013, Pages 3539-3551

  Li, Jian Hua ^a   Jain, Shalini ^a   McMillin, Sara M ^a   Cui, Yinghong ^a   Gautam, Dinesh ^a   Sakamoto, Wataru ^a   Lu, Huiyan ^a   Jou, William ^a   McGuinness, Owen P ^b   Gavrilova, Oksana ^a   Wess, Jur̈gen ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR; CLOZAPINE N OXIDE; COMPLEMENTARY DNA; G PROTEIN COUPLED RECEPTOR; GLUCAGON RECEPTOR; GLUCOSE; GLYCOGEN; MUSCARINIC M3 RECEPTOR; PHOSPHOENOLPYRUVATE; THROMBIN; URIDINE DIPHOSPHATE GLUCOSE; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V1B RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALCIUM MOBILIZATION; CONTROLLED STUDY; GENE EXPRESSION; GENOTYPE; GLUCONEOGENESIS; GLUCOSE TOLERANCE TEST; GLYCOGENOLYSIS; IN VITRO STUDY; IN VIVO STUDY; INSULIN TOLERANCE TEST; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE;

ANIMALS; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; ENZYME ACTIVATORS; FEMALE; G-PROTEIN-COUPLED RECEPTOR KINASES; GLUCONEOGENESIS; GLYCOGENOLYSIS; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; HEPATOCYTES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, OBESE; MICE, TRANSGENIC; PROTEIN ENGINEERING; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECEPTOR, MUSCARINIC M3; RECEPTORS, VASOPRESSIN; RECOMBINANT FUSION PROTEINS; SPECIFIC PATHOGEN-FREE ORGANISMS;

EID: 84884687446     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-2127     Document Type: Article

References (38)

1. Taylor SI. Deconstructing type 2 diabetes. Cell. 1999;97:9-12. (Pubitemid 29165884)
2. Postic C, Dentin R, Girard J. Role of the liver in the control of carbohydrate and lipid homeostasis. Diabetes Metab. 2004;30:398-408. (Pubitemid 39648006)
3. Lin HV, Accili D. Hormonal regulation of hepatic glucose production in health and disease. Cell Metab. 2011;14:9-19.
4. Regard JB, Sato IT, Coughlin SR. Anatomical profiling of G protein-coupled receptor expression. Cell. 2008;135:561-571.
5. Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab. 2003;284:E671-E678. (Pubitemid 36323859)
6. Estall JL, Drucker DJ. Glucagon and glucagon-like peptide receptors as drug targets. Curr Pharm Des. 2006;12:1731-1750.
7. Cho YM, Merchant CE, Kieffer TJ. Targeting the glucagon receptor family for diabetes and obesity therapy. Pharmacol Ther. 2012;135:247-278.
8. Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest. 2012;122:4-12.
9. D'Alessio D. The role of dysregulated glucagon secretion in type 2 diabetes. Diabetes Obes Metab. 2011;13(Suppl 1):126-132.
10. Wess J. Molecular basis of receptor/G-protein-coupling selectivity. Pharmacol Ther. 1998;80:231-264. (Pubitemid 28537822)
11. Exton JH, Blackmore PF, El-Refai MF, et al. Mechanisms of hormonal regulation of liver metabolism. Adv Cyclic Nucleotide Res. 1981;14:491-505.
12. 2+ signals: direct evidence in rat hepatocytes. J Hepatol. 2003;39:489-495.
13. Li JH, Gautam D, Han SJ, et al. Hepatic muscarinic acetylcholine receptors are not critically involved in maintaining glucose homeostasis in mice. Diabetes. 2009;58:2776-2787.
14. ArmbrusterBN,Li X, PauschMH,Herlitze S, Roth BL. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc Natl Acad Sci U S A. 2007;104:5163-5168. (Pubitemid 47186193)
15. Conklin BR, Hsiao EC, Claeysen S, et al. Engineering GPCR signaling pathways with RASSLs. Nat Methods. 2008;5:673-678.
16. Guettier JM, Gautam D, Scarselli M, et al. A chemical-genetic approach to study G protein regulation of beta cell function in vivo. Proc Natl Acad Sci U S A. 2009;106:19197-19202.
17. Conner EA, Lemmer ER, Omori M, Wirth PJ, Factor VM, Thorgeirsson SS. Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis. Oncogene. 2000;19:5054-5062.
18. Jaruga B, Hong F, Kim WH, Gao B. IFN-γ/STAT1 acts as a proinflammatory signal in T cell-mediated hepatitis via induction of multiple chemokines and adhesion molecules: a critical role of IRF-1. AmJ Physiol Gastrointest Liver Physiol. 2004;287:G1044-G1052. (Pubitemid 39423697)
19. Li B, Scarselli M, Knudsen CD, Kim SK, Jacobson KA, McMillin SM, Wess J. Rapid identification of functionally critical amino acids in a G protein-coupled receptor. Nat Methods. 2007;4:169-174. (Pubitemid 46454686)
20. Korzeniowski MK, Manjarrés IM, Varnai P, Balla T. Activation of STIM1-Orai1 involves an intramolecular switching mechanism. Sci Signal. 2010;3:ra82.
21. Gelling RW, Du XQ, Dichmann DS, et al. Lower blood glucose, hyperglucagonemia, and pancreatic α-cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad SciUSA. 2003;100:1438-1443. (Pubitemid 36184020)
22. Ayala JE, Bracy DP, McGuinness OP, Wasserman DH. Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes. 2006;55:390-397. (Pubitemid 43343268)
23. Ayala JE, Samuel VT, Morton GJ, et al. Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice. Dis Model Mech. 2010;3:525-534.
24. Ayala JE, Bracy DP, Malabanan C, et al. Hyperinsulinemic-euglycemic clamps in conscious, unrestrained mice. J Vis Exp. 2011; e3188.
25. Wall JS, Steele R, De Bodo RC, Altszuler N. Effect of insulin on utilization and production of circulating glucose. Am J Physiol. 1957;189:43-50.
26. Giaccari A, Rossetti L. Isocratic high-performance liquid chromatographic determination of the concentration and specific radioactivity of phosphoenolpyruvate and uridine diphosphate glucose in tissue extracts. J Chromatogr. 1989;497:69-78. (Pubitemid 20027103)
27. Fujimoto Y, Donahue EP, Shiota M. Defect in glucokinase translocation in Zucker diabetic fatty rats. AmJ Physiol Endocrinol Metab. 2004;287:E414-E423. (Pubitemid 39095874)
28. Turner SM, Linfoot PA, Neese RA, Hellerstein MK. Sources of plasma glucose and liver glycogen in fasted ob/ob mice. Acta Diabetol. 2005;42:187-193. (Pubitemid 43029839)
29. Serradeil-Le Gal C, Wagnon J, Simiand J, et al. Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-me-thoxy- phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl- 2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J Pharmacol Exp Ther. 2002;300:1122-1130. (Pubitemid 34165020)
30. Griebel G, Stemmelin J, Gal CS, Soubrié P. Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders. Curr Pharm Des. 2005;11:1549-1559. (Pubitemid 40691451)
31. Oshikawa S, Tanoue A, Koshimizu TA, Kitagawa Y, Tsujimoto G. Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach. Mol Pharmacol. 2004;65:623-629. (Pubitemid 38264029)
32. Roper J, O'Carroll AM, Young W 3rd, Lolait S. The vasopressin Avpr1b receptor: molecular and pharmacological studies. Stress. 2011;14:98-115.
33. Blackmore PF, Hughes BP, Shuman EA, Exton JH. α- Adrenergicactivation of phosphorylase in liver cells involves mobilization of intracellular calcium without influx of extracellular calcium. J Biol Chem. 1982;257:190-197.
34. Reinhart PH, Taylor WM, Bygrave FL. The role of calcium ions in the mechanism of action of alpha-adrenergic agonists in rat liver. Biochem J. 1984;223:1-13. (Pubitemid 15220344)
35. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004;88:787-835, ix. (Pubitemid 39090340)
36. Alvarez-Curto E, Prihandoko R, Tautermann CS, et al. Developing chemical genetic approaches to explore G protein-coupled receptor function: validation of the use of a receptor activated solely by synthetic ligand (RASSL). Mol Pharmacol. 2011;80:1033-1046.
37. Nakajima K, Wess J. Design and functional characterization of a novel, arrestin-biased designer G protein-coupled receptor. Mol Pharmacol. 2012;82:575-582.
38. Patel HH,Murray F, Insel PA. G-protein-coupled receptor-signaling components in membrane raft and caveolae microdomains. Handb Exp Pharmacol. 2008;186:167-184.